Vaccine specialist and COVID-19 antagonist Moderna (MRNA) had a busy Thursday, issuing press releases and holding conference calls to discuss what it had said in the press releases already.Three major subjects for discussion were covered over the course of the day, and in a note updating investors on its opinion of Moderna, JPMorgan analyst Cory Kasimov discussed them all. Let’s begin with the most urgent question of the day: Coronavirus, and Moderna’s mRNA-1273 vaccine to prevent getting infected with it.Kasimov notes that Moderna unveiled “a few incremental data points” on its COVID-19 vaccine. Moderna is looking to get, and disclose …read more
Source:: Yahoo Finance
